Overview
Employees
11-50
Total raised
$68M
Founded date
2013
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Nov 17, 2016 | Series A round | $8M | |
| Mar 22, 2016 | Series A round | $10M |
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 27, 2018 | Alexion To Acquire Syntimmune, for Up To $1.2 Billion | Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), a a global biopharmaceutical company, is to acquire Syntimmune, a Boston, Mass.-based clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcR... |
| Jul 13, 2018 | George Golumbeski's first stop out of Celgene: Grail; Roivant taps Genentech vet Myrtle Potter for operations role | → Three months after quietly slipping out the back door at Celgene, George Golumbeski has taken up the president role at the cancer detection startup Grail in a similarly discreet manner. The former BD chief — noted for ... |
| Jun 21, 2017 | Syntimmune Raises $50M Series B | NEW YORK--(BUSINESS WIRE)--Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with add... |
| Jun 21, 2017 | Term Sheet — Wednesday, June 21 | YES, MORE UBER 🚨 Travis Kalanick is permanently out as CEO of Uber.🚨 Paid Content What you need to know about growing cyberattacks From ExtraHop • Investors did this. Benchmark, First Round Capital, Lowercase Capital, Menlo Ventures, and Fi... |
| Jun 21, 2017 | Syntimmune Closes $50M in Series B Financing | Syntimmune, Inc., a NYC-based clinical-stage biotechnology company focused on FcRn biology, raised $50m in Series B financing. The round was led by Apple Tree Partners, which has committed $48 million to the round, with additional participa... |
| Nov 17, 2016 | Syntimmune Raises $8M Tranche of $26M Series A Funding | Syntimmune, Inc., a Newton, MA- and New York, NY-based clinical-stage biotechnology company, raised the latest $8m tranche of its $26m Series A financing. Investors include Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund... |
| Mar 22, 2016 | Syntimmune Raises Second $10M Tranche of $26M Series A Financing | Syntimmune, Inc., a New York-based development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on expertise in FcRn biology, raised a second $10m tranche of its $26m Series A financing. The round is co-le... |
| Mar 22, 2016 | Daily funding roundup - March 22, 2016 | Syntimmune bagged $26M; FineHeart recieved investment from Broadview Ventures; Shiftboard landed $4M St. Louis, Missouri-based ClubReady, a software provider for the fitness and wellness industry, closed a Series A investment from Level Equ... |
| Mar 22, 2016 | UPDATED: Fledging biotech Syntimmune gains $10M tranche from its Series A nest egg | New York biotech Syntimmune has hit its targets in preclinical testing and been given a $10 million gift for its efforts. The autoimmune disease specialist that works under a virtual model achieved preclinical proof of concept and hit its p... |
Show more
Reviews 0
FAQ about Syntimmune
When was Syntimmune founded?
Syntimmune was founded in 2013.
How much funding has Syntimmune raised?
Syntimmune has raised $68M in total across 3 funding rounds.
What funding rounds has Syntimmune raised?
Parsers VC lists 3 funding rounds of Syntimmune, among them a Series A round of $8M on Nov 17, 2016 and a Series A round of $10M on Mar 22, 2016.
What has the press written about Syntimmune?
Parsers VC has collected 12 articles mentioning Syntimmune, among them “Alexion To Acquire Syntimmune, for Up To $1.2 Billion” (Sep 27, 2018) and “George Golumbeski's first stop out of Celgene: Grail; Roivant taps Genentech vet Myrtle Potter for operations role” (Jul 13, 2018).
Is Syntimmune still active?
Yes, Syntimmune is active; its latest activity on Parsers VC dates from Jun 13, 2024.